A Trial of Hetrombopag in Healthy Subjects

A Single-Center, Single-Arm, Open-Label, Self-Controlled, Drug-Drug Interaction Study of Hetrombopag Olamine and Ciclosporin in Healthy Subjects

This is a single-center, single-arm, open-label, self-controlled, phase I clinical study. A total of 26 male or female healthy subjects are intended to be enrolled to evaluate the PK drug-drug interaction between ciclosporin and hetrombopag.

Study Overview

• Status: Completed
• Conditions: Sever Aplastic Anaemia
• Intervention / Treatment: Drug: Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule

• Study Type: Interventional
• Enrollment (Actual): 26
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Sichuan
    • Chengdu, Sichuan, China, 610041
      • West China Second University Hospital Ethics Committee

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Voluntarily sign the informed consent form prior to any study-related activities, understand the procedures and methods of the study, and agree to complete this study in strict accordance with the clinical study protocol;
2. Male or female subjects aged 18-55 years (inclusive);
3. Body mass index (BMI) between 18 and 26 kg/m2 (inclusive);
4. Normal or abnormal but not clinically significant physical examination and laboratory test results; normal or abnormal but not clinically significant ECG;
5. Have no plan for pregnancy and agree to take effective contraceptive measures from signing of informed consent form until 6 months after the last dose;
6. Able to maintain a consistency of good communication with the investigators, and understand and comply with all the requirements of this study

Exclusion Criteria:

1. Any previous or current serious clinical conditions of the circulatory system, endocrine system, nervous system, digestive system, respiratory system, and hematological, immunological, psychiatric and metabolic abnormalities, or any disease that may interfere with the results of this study;
2. History of deep venous thrombosis or other thrombotic disorders;
3. QTc > 450 ms in males or QTc > 460 ms in females through 12-lead ECG examination with clinical significance per the investigator's judgment at screening;
4. Positive for hepatitis B surface antigen, hepatitis C antibody, syphilis antibody (trust), or HIV antibody;
5. Positive pregnancy test result;
6. Allergic constitution, or allergy to any component of hetrombopag olamine tablets and ciclosporin capsules;
7. Have received surgery within 4 weeks before the first study administration, or plan to undergo surgery during the course of the study;
8. Have taken any drug that alters liver enzyme activity within 28 days before the first study administration or during the study;
9. Have taken any prescription drug, over-the-counter drug, herbal medicine, or health supplements within 14 days before the first study administration, or within 5 half-lives of the drug at screening; plan to take non-study drugs or health supplements during the study;
10. Consumption of grapefruit or grapefruit-containing products, foods or beverages containing caffeine, xanthine, or alcohol within 48 h before the first study administration; strenuous exercise, or other factors that affect drug absorption, distribution, metabolism, and excretion;
11. Have participated in any drug clinical trial and have been treated with any investigational drug or medical device within 3 months before the first study administration (per the date of signing the informed consent form);
12. Have blood donation (or blood loss) of ≥ 400 mL or have received blood transfusion within 3 months before screening;
13. Unable or unwilling to comply with the lifestyle requirements in the protocol;
14. Addicted to smoking (≥ 5 cigarettes per day within 1 month before screening);
15. Average daily alcohol consumption of > 15 g for females (e.g., 145 mL of wine, 497 mL of beer, or 43 mL of low-alcohol liquor) and > 25 g for males (e.g., 290 mL of wine, 994 mL of beer, or 86 mL of low-alcohol liquor) within 1 month before screening;
16. History of drug abuse, history of drug dependence, or drug abuse screening positive (drugs include morphine, methamphetamine, ketamine, ecstasy (dimethylene dioxyamphetamine), and cannabis (tetrahydrocannabinol)) (consultation and examination), or history of drug abuse within the past five years or have used narcotics within 3 months before the study;
17. Potentially unable to complete the study for other reasons or judged by the investigator as not suitable for the study.
18. Intolerant to venipuncture, or history of hemophobia or fear of needles;
19. Have special dietary requirements and unable to accept a standardized diet;
20. Acute disease from screening to first study administration.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: D1：hetrombopag single dose，D11-D15：cyclosporine,D16 combination use of hetrombopag and cyclosporine	Drug: Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule; Drug: Hetrombopag Olamine Tablet Ciclosporin Soft Capsule

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Peak hetrombopag plasma concentration (Cmax)	0-120 hours post dose
Area Under the plasma hetrombopag concentration vs time curve (AUC0-120)	0-120 hours post dose
Area under the plasma hetrombopag concentration vs time curve (AUC0-inf)	0-infinity

Secondary Outcome Measures

Outcome Measure	Time Frame
Time to Reach Maximum Drug Concentration in Plasma After Single Dose (Tmax)	0-120 hours post dose
Half-life Associated With the Terminal Slope (t½)	0-120 hours post dose
The number of volunteers with adverse events as a measure of safety and tolerability	up to Day 22

Collaborators and Investigators

• Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): September 3, 2020
• Primary Completion (Actual): October 22, 2020
• Study Completion (Actual): October 22, 2020

Study Registration Dates

• First Submitted: October 12, 2021
• First Submitted That Met QC Criteria: October 12, 2021
• First Posted (Actual): October 21, 2021

Study Record Updates

• Last Update Posted (Actual): October 21, 2021
• Last Update Submitted That Met QC Criteria: October 12, 2021
• Last Verified: October 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Bone Marrow Diseases; Hematologic Diseases; Anemia; Bone Marrow Failure Disorders; Anemia, Aplastic; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Antirheumatic Agents; Immunosuppressive Agents; Immunologic Factors; Dermatologic Agents; Antifungal Agents; Calcineurin Inhibitors; Cyclosporine; Cyclosporins
• Other Study ID Numbers: SHR8735-111

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No